← Back to Screener
Biogen Inc. Common Stock (BIIB)
Price$195.34
Value ScoreB
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-0.65%
Price vs S&P 500 (4W)0.99%
VGM Score54.49
Market Capitalization$28.84B
P/E Ratio (Annual)22.31x
All Metrics
P/CF (Annual)13.08x
Book Value / Share (Quarterly)$126.37
P/TBV (Annual)2.84x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.93%
Cash Flow / Share (Quarterly)$16.03
Price vs S&P 500 (YTD)2.84%
Gross Margin (TTM)75.49%
Net Profit Margin (TTM)13.81%
EPS (TTM)$9.32
10-Day Avg Trading Volume0.96M
EPS Excl Extra (TTM)$9.32
Revenue Growth (5Y)-5.96%
EPS (Annual)$8.79
ROI (Annual)5.27%
Gross Margin (Annual)75.99%
Net Profit Margin (5Y Avg)17.17%
Cash / Share (Quarterly)$29.02
P/E Basic Excl Extra (TTM)21.02x
Revenue Growth QoQ (YoY)1.93%
EPS Growth (5Y)-18.77%
P/E Normalized (Annual)22.31x
ROA (Last FY)4.39%
Revenue Growth TTM (YoY)1.23%
EBITD / Share (TTM)$15.40
ROE (5Y Avg)12.34%
Operating Margin (TTM)17.47%
Cash Flow / Share (Annual)$13.76
P/B Ratio1.55x
P/B Ratio (Quarterly)1.44x
Net Income / Employee (Annual)$172,400
EV / Revenue (TTM)3.19x
Net Interest Coverage (TTM)4.24x
ROA (TTM)4.71%
EPS Growth QoQ (YoY)31.24%
EV / EBITDA (TTM)14.00x
EPS Incl Extra (Annual)$8.79
Current Ratio (Annual)2.68x
Quick Ratio (Quarterly)2.41x
3-Month Avg Trading Volume1.21M
52-Week Price Return49.85%
EV / Free Cash Flow (Annual)15.72x
P/E Incl Extra (TTM)21.02x
Revenue / Employee (TTM)$1,325,000
Tangible BV / Share (Quarterly)$65.03
P/S Ratio (Annual)2.92x
Asset Turnover (Annual)0.34x
52-Week High$205.97
Operating Margin (5Y Avg)24.59%
EPS Excl Extra (Annual)$8.79
CapEx CAGR (5Y)-19.60%
Tangible BV CAGR (5Y)3.58%
26-Week Price Return7.28%
Quick Ratio (Annual)1.82x
13-Week Price Return3.86%
Total Debt / Equity (Annual)0.34x
Current Ratio (Quarterly)3.06x
Enterprise Value$31.75B
Revenue / Share Growth (5Y)-4.24%
Asset Turnover (TTM)0.34x
Book Value / Share Growth (5Y)12.07%
Revenue / Employee (Annual)$1,318,700
Inventory Turnover (Annual)1.03x
Pretax Margin (Annual)15.74%
Cash / Share (Annual)$26.01
3-Month Return Std Dev33.06%
Gross Margin (5Y Avg)77.42%
Net Income / Employee (TTM)$182,900
EBITDA CAGR (5Y)-14.23%
EBITDA Interim CAGR (5Y)-12.43%
ROE (Last FY)7.08%
Net Interest Coverage (Annual)4.66x
EPS Basic Excl Extra (Annual)$8.79
P/FCF (TTM)12.19x
Receivables Turnover (TTM)5.25x
EV / Free Cash Flow (TTM)13.42x
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$9.32
Receivables Turnover (Annual)5.29x
ROI (TTM)5.61%
P/S Ratio (TTM)2.90x
Pretax Margin (5Y Avg)19.96%
Revenue / Share (Annual)$67.24
Tangible BV / Share (Annual)$61.88
Forward P/E12.84x
Free OCF CAGR (5Y)-11.30%
Price vs S&P 500 (52W)25.48%
P/E Ratio (TTM)21.02x
EPS Growth TTM (YoY)-8.05%
Year-to-Date Return10.99%
5-Day Price Return1.62%
EPS Normalized (Annual)$8.79
ROA (5Y Avg)6.69%
Net Profit Margin (Annual)13.07%
Month-to-Date Return-0.34%
Cash Flow / Share (TTM)$13.34
EBITD / Share (Annual)$15.16
EPS Growth (3Y)-25.04%
Operating Margin (Annual)17.42%
LT Debt / Equity (Annual)0.34x
P/CF (TTM)11.13x
ROI (5Y Avg)8.35%
P/E Excl Extra (TTM)21.02x
LT Debt / Equity (Quarterly)0.34x
EPS Basic Excl Extra (TTM)$9.32
P/TBV (Quarterly)2.80x
P/B Ratio (Annual)1.41x
Inventory Turnover (TTM)1.15x
Pretax Margin (TTM)16.33%
Book Value / Share (Annual)$124.45
Price vs S&P 500 (13W)-4.39%
Net Margin Growth (5Y)-15.17%
Beta0.18x
P/FCF (Annual)14.28x
Revenue / Share (TTM)$66.96
ROE (TTM)7.54%
52-Week Low$121.05
vGradeB
gGradeD
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 263.57est. 2.83
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.67
3.65
3.65
3.74
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $71.53 |
About
Biogen is a biopharmaceutical company focused on neurodegenerative and rare diseases. Its revenue base is anchored by multiple sclerosis therapies (40% of 2025 revenue) and a CD20 collaboration with Roche (19%), though the MS franchise is declining. The company is diversifying through emerging treatments including Leqembi for Alzheimer's disease, Spinraza for spinal muscular atrophy, and programs addressing postpartum depression, Friedreich's ataxia, and amyotrophic lateral sclerosis.